Earnings ·
Aura Biosciences reported a net loss of $45.6 million for Q2 2026 and announced an organizational realignment to focus…
AURAAura Biosciences, Inc.
Aura Biosciences reported a net loss of $45.6 million for Q2 2026 and announced an organizational realignment to focus on ocular oncology, reducing its workforce by approximately 20% with estimated restructuring costs of $2.9–$3.2 million. The company appointed Susan Abu-Absi as Chief Operating Officer and Amy Elazzouzi as interim principal financial officer following the departure of CFO Anthony Gibney. Phase 3 CoMpass trial enrollment is complete, with topline data expected in H2 2027, while the NMIBC program is being deprioritized. Aura holds $323.8 million in cash and expects its runway to extend into the first half of 2029. The company operates as a clinical-stage biotechnology firm developing bel-sar for ocular cancers.